Moncef Slaoui has stepped down from positions at three more companies, shortly after being dismissed from a firm owned by GlaxoSmithKline for alleged sexual harassment. In the space of 24 hours ...

GlaxoSmithKline has fired its former research boss Moncef Slaoui from the board of Galvani Bioelectronics, a company it majority owns, after an internal investigation found he sexually harassed a ...

Dr. Slaoui's career includes a tenure as the Chief Scientific Advisor to Operation Warp Speed, where he played a pivotal role in the rapid development and distribution of COVID-19 vaccines.

View Full Profile. Learn about our Editorial Policies. Moncef Slaoui, the former head of the US government’s COVID-19 vaccine initiative called Operation Warp Speed, has been fired from the Galvani ...

Operation Warp Speed chief adviser Dr. Moncef Slaoui said recruitment for the British drugmaker's late-stage U.S. trial is almost complete with over 29,000 participants enrolled. “We project ...

Even though he is seen amongst the most praised doctors in terms of the COVID19 response in the US, leading the Operation Warp Speed vaccine effort as appointed by the ex-Trump administration ...

Some of the brains behind Shingrix’s success will be heading over to Curevo, with the company revealing that it is adding ...

But Moncef Slaoui, the head of the US government's effort to deliver a vaccine, says there is now "light at the end of the tunnel". With hopes a vaccine could be approved this week, Dr Slaoui told ...

On Friday, President Trump announced that Moncef Slaoui, former vaccine chief at GlaxoSmithKline and Gustave Perna, a four star general, would oversee the initiative, which was first reported in ...

A leader in vaccine research in the US, Dr Moncef Slaoui said that he was asked the same questions from President of the European Commission Ursula von der Leyen, French President Emmanuel Macron ...

Curevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former executive from the UK big pharma to advance its candidate amezosvatein.